<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160415</url>
  </required_header>
  <id_info>
    <org_study_id>EDG-5506-002</org_study_id>
    <nct_id>NCT05160415</nct_id>
  </id_info>
  <brief_title>A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy</brief_title>
  <acronym>ARCH</acronym>
  <official_title>A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edgewise Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Edgewise Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ARCH study is an open-label, single-center, Phase 1b study of EDG-5506 to assess the&#xD;
      safety and pharmacokinetics (PK) of EDG-5506 in adults with Becker muscular dystrophy (BMD).&#xD;
&#xD;
      EDG-5506 is an investigational product intended to protect and improve function of dystrophic&#xD;
      muscle fibers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label study will evaluate the safety, tolerability, and pharmacokinetics (PK) of&#xD;
      EDG-5506 in participants with BMD who completed the first-in-human study, EDG-5506-001, as&#xD;
      well as additional (treatment-naïve) participants from outside the EDG-5506-001 study to meet&#xD;
      the target sample size.&#xD;
&#xD;
      All participants will receive EDG-5506. Monthly on-site visits will occur to assess safety&#xD;
      and measures of function. This study will have a 3 month treatment period, followed by a 4&#xD;
      week follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs in those treated with EDG-5506</measure>
    <time_frame>Up to 113 days of monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of AEs in those treated with EDG-5506</measure>
    <time_frame>Up to 113 days of monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of AEs in those treated with EDG-5506</measure>
    <time_frame>Up to 113 days of monitoring</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent abnormal clinical chemistry test results</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent abnormal hematology test results</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent abnormal coagulation test results</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent abnormal urinalysis test results</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in clinical chemistry</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in hematology</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in coagulation</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in urinalysis</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in vital signs</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in physical examination</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in ECG PR Interval</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in ECG QRS Interval</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in ECG QT Interval</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in ECG QTc Interval</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in FVC</measure>
    <time_frame>3 Months</time_frame>
    <description>Assessed by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in FEV1</measure>
    <time_frame>3 Months</time_frame>
    <description>As assessed by spirometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with changes in biomarkers of muscle fiber damage</measure>
    <time_frame>3 Months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: EDG-5506&#xD;
All participants will receive EDG-5506.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDG-5506</intervention_name>
    <description>Daily oral dose</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who have completed Study EDG-5506-001.&#xD;
&#xD;
          2. Participants who were not from Study EDG-5506-001 must meet the following:&#xD;
&#xD;
               1. Male sex at birth and aged 18 to 55 years inclusive at time of consent.&#xD;
&#xD;
               2. Documented dystrophin mutation with phenotype consistent with BMD.&#xD;
&#xD;
               3. Ambulatory at Screening (defined as ability to complete 100 meter [m] timed test,&#xD;
                  with or without assistance).&#xD;
&#xD;
               4. Body weight ≥ 50 kg at the Screening visit.&#xD;
&#xD;
               5. Body mass index (BMI) between 20 and 34 kg/m2 inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of oral corticosteroids for &gt;5 days in the previous 6 months at a dose of &gt;5&#xD;
             mg equivalent per day. Lower oral doses or inhaled/intranasal steroids are permitted.&#xD;
&#xD;
          2. Receiving moderate or strong cytochrome P450 CYP3A4 inhibitors or inducers.&#xD;
&#xD;
          3. Participation in any other investigational drug study or use of use of an&#xD;
             investigational drug within 30 days or 5 half-lives (whichever is longer) of dosing in&#xD;
             the present study.&#xD;
&#xD;
          4. Medical history or other medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation/behavior or laboratory result or abnormality&#xD;
             that may increase the risk of study participation or, in the Investigator's judgment,&#xD;
             make the participant inappropriate for the study. Includes venous access that would be&#xD;
             too difficult to facilitate repeated blood sampling.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Collins, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Edgewise Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edgewise Therapeutics</last_name>
    <phone>678-883-6897</phone>
    <email>studies@edgewisetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rare Disease Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Deanna Baker</last_name>
      <phone>678-883-6897</phone>
      <email>deanna.baker@rarediseaseresearch.com</email>
    </contact>
    <investigator>
      <last_name>Han Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.edgewisetx.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Becker Muscular Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

